1. Introduction {#sec1-cancers-12-00855}
===============

Cancer is one of the leading causes of mortality, resulting in one in six deaths (or 9.6 million people) in 2018 alone; however, 70% of deaths from cancer occur in middle- and low-income countries \[[@B1-cancers-12-00855]\]. Surgery, chemotherapy, radiation therapy and hormone therapy are the most common approaches for cancer treatment and management. In recent years, therapeutic and diagnostic approaches based on nanotechnology have shown potential to improve cancer therapy \[[@B2-cancers-12-00855]\]. Cancer nanotechnology unfolded a newer horizon of interdisciplinary research across chemistry, medicine, engineering and biology focusing on the major advancement in cancer detection, diagnosis and treatment \[[@B3-cancers-12-00855]\]. In recent years, nanoparticles (NPs) have gained an immense scientific attraction due to their large surface area to volume ratio and high reactivity with unmatchable properties \[[@B4-cancers-12-00855]\]. Recently, nanotechnology-based anticancer drugs, such as Abraxane^®^ (Celgene, Summit, NJ, USA), Doxil^®^ (Johnson & Johnson, New Brunswick, NJ, USA) and Myocet^™^ (Perrigo, Dublin, Ireland), have been approved by the US Food and Drug Administration for clinical use \[[@B5-cancers-12-00855]\].

Particles with at least one dimension smaller than 100 nm are defined as NPs. Their physical (e.g., plasmon resonance and fluorescent enhancement) and chemical (e.g., catalytic activity enhancement) properties arise from their surface geometry, which determines the area/volume ratio. When NPs diameter decreases for a spherical particle, the surface area increases proportionately to the square of diameter and there is a resulting increase of surface activity compared to bulk materials with larger dimensions. In some cases, a decrease in size combined with an increase in the area can improve material biocompatibility \[[@B6-cancers-12-00855]\]. Although nanotechnology is one of the most promising research fields and is currently viewed as a frontier in medicine, only a few nanoproducts are currently considered for bio-application due to their potential toxicity and unknown safety. Silver, a precious metal, has been widely used in medicine since ancient times. Hippocrates, the father of modern medicine, believed that silver could treat disease and promote wound healing \[[@B7-cancers-12-00855]\]. It has fascinating material properties, which are cost-effective as well as abundant in nature compared to other precious metals. Previous studies revealed that the physical, optical and catalytic properties of silver nanoparticles (AgNPs) are strongly influenced by their size, distribution, morphologic shape and surface properties \[[@B8-cancers-12-00855]\]. Hereafter, AgNPs have received considerable attention from scientists for their unique properties \[[@B9-cancers-12-00855]\].

Metallic NPs such as silver, gold and platinum NPs have been widely tested in humans. For medicinal applications, NPs synthesis must be biocompatible and either non-toxic or low-toxicity protocols should be used. The most common method which has been used to produce AgNPs is chemical synthesis, recruiting reagents whose function is to reduce the silver ions and stabilize the nanoparticles. However, these reagents are toxic and may have potential health hazards \[[@B10-cancers-12-00855]\]. In addition, these production methods are usually expensive and labor-intensive. To address this issue, approaches for AgNPs synthesis through green chemistry (such as the use of biologic sources) have shown great promise recently. During the past decade, it has been demonstrated that many biologic systems, including plants, algae, bacteria, yeast and fungi can transform inorganic metal ions into metal nanoparticles via the reductive capacities of the proteins and metabolites present in these organisms. Biologic methods of AgNPs synthesis have been reported using plants \[[@B11-cancers-12-00855],[@B12-cancers-12-00855]\], bacteria \[[@B13-cancers-12-00855]\], fungi \[[@B14-cancers-12-00855],[@B15-cancers-12-00855]\], seaweed \[[@B16-cancers-12-00855]\], algae \[[@B17-cancers-12-00855]\] and lichen \[[@B18-cancers-12-00855]\]. These eco-friendly methods can present alternatives methods to chemical and physical syntheses of AgNPs. Physicochemical properties of AgNPs can have a significant impact on their biologic activity, therefore particle characterization is normally completed after synthesis \[[@B19-cancers-12-00855]\]. In addition, AgNPs synthesized using biologic approaches typically retain a homogenous chemical composition with few defects \[[@B20-cancers-12-00855]\]. These AgNPs show promising activity against a range of cancer cell lines. Such eco-friendly methods provide alternatives to the traditional chemical and physical synthesis of AgNPs for use in anti-cancer treatments.

AgNPs can cause cytotoxicity of the cancer cells by altering their morphology and reducing the viability along with oxidative stress in different cancer cells \[[@B21-cancers-12-00855],[@B22-cancers-12-00855]\]. In addition, AgNPs play a pivotal role in tumor control via their cytotoxic effects \[[@B23-cancers-12-00855]\]. The purpose of this review is to provide an overview of the main published studies concerning the use of biologic synthesis of silver nanoparticles and the applications of these materials in different cancer cell lines. Several biologic synthesis mechanisms of AgNPs are discussed together with the importance of biologically synthesized AgNPs on cancer cell lines.

2. Properties of AgNPs {#sec2-cancers-12-00855}
======================

Unique physicochemical properties of AgNPs provides them the ease of entrance into the cells and gives them the ability to efficiently interact with biomolecules inside the cells or on the cell surfaces \[[@B24-cancers-12-00855]\]. Some of the crucial properties of the AgNPs are described below.

2.1. Shape and Size {#sec2dot1-cancers-12-00855}
-------------------

While picking a drug material for the treatment of certain disease types including cancer, hemocompatibility of that material should be kept in mind \[[@B25-cancers-12-00855]\]. Kwon et al. demonstrated the minimization of the damage to membrane including hemolysis, potassium efflux, protein leakage and alterations in cell shape and membrane fragility by the use of AgNPs of specific shape and size \[[@B26-cancers-12-00855]\]. Therefore, AgNPs have been evidenced to have great potential in anti-cancer activity since they show selective participation in the interruption of mitochondrial respiratory chain that leads to the production of reactive oxygen species (ROS) and disruption of adenosine triphosphate (ATP) synthesis, thus resulting in nucleic acid damage \[[@B27-cancers-12-00855]\]. Various studies have established that temperature, pH of the solution, precursor concentration, the molar ratio of capping agent to that of precursor, the types of reducing agents, the strength of chemical interaction between the precursor and different crystallographic planes of AgNPs and the synthesis method determine the size and shape of the AgNPs \[[@B28-cancers-12-00855]\]. Depending on the synthesis methods, a range of particle sizes and shapes (e.g., cubes, prisms, spheres, rods, wires, plates, etc.) can be obtained \[[@B29-cancers-12-00855]\]. For instance, in the synthesis of AgNPs from the bacteria *Xanthomonas oryzae*, spherical as well as triangular and rod-shaped particles with an average size of 14.86 nm were obtained depending on the experimental conditions \[[@B30-cancers-12-00855]\], whereas bacterial synthesis from *Pseudomonas stutzeri* AG259 resulted in triangular and hexagonal particles with an average size of 200 nm \[[@B31-cancers-12-00855]\]. In the fungal synthesis from *Fusarium acuminatum*, spherical AgNPs in the range of 5--40 nm (average size 13 nm) were reported \[[@B32-cancers-12-00855]\]. On the other hand, AgNPs synthesis from the fungus *Trichoderma viride*, spherical and sporadically rod-like particles in the range of 10--40 nm at 27 °C. Decreasing the temperature to 10 °C increased the particle size to 80--100 nm \[[@B15-cancers-12-00855]\]. Studies have established that low reaction temperatures can facilitate the formation of two-dimensional nanostructures \[[@B33-cancers-12-00855]\]. To underscore the range of sizes and shapes of AgNPs which plant-based green synthesis can yield, the study on *Nelumbo nucifera* can be used as an example. Synthesis using the leaf extract of this plant resulted in AgNPs with spherical, triangular, truncated triangular and decahedral morphologies. Sizes of the particles ranged between 25 and 80 mm averaging 45 mm \[[@B34-cancers-12-00855]\]. Vilchis-Nestor et al. reported more spherical and larger AgNPs under ambient conditions with the increase in the concentration of the *Camellia sinensis* (green tea) extracts \[[@B35-cancers-12-00855]\].

2.2. Optical Properties {#sec2dot2-cancers-12-00855}
-----------------------

AgNPs efficiently interact with light through a phenomenon known as surface plasmon resonance (SPR) more efficiently than any known organic or inorganic chromophores. This strong interaction is a result of both the restriction of a large density of conducting electrons to smaller dimensions compared to the mean free path and the unique frequency dependence of the dielectric function in metallic silver. The combination of these two factors gives rise to SPR related properties. The size and shape of NPs and the dielectric function of the surrounding medium determines the frequency and resonance strength \[[@B36-cancers-12-00855]\]. The light-interaction cross-sections of AgNPs is dependent on the photon electric field which can extend up to 10 times larger than the geometric cross-sections of the AgNPs. As such, these structures are capable of interaction with light photons that are not physically incident upon them \[[@B37-cancers-12-00855],[@B38-cancers-12-00855]\]. Because of the unique optical characteristics of the AgNPs, non-invasive techniques like dark-field microscopy or surface-enhanced Raman Scattering can be utilized for the inspection of their tracking and cellular uptake \[[@B39-cancers-12-00855]\]. Certain optical characteristics of AgNPs can be modified to obtain interesting results. For example, the absorption spectrum of AgNPs is tunable through careful optimization of the synthesis conditions to the near-infrared region. This eliminates the interference from tissue auto-fluorescence, resulting in NPs which have great promise in tumor-targeting and deep tissue-imaging \[[@B40-cancers-12-00855]\].

2.3. Electrical Properties {#sec2dot3-cancers-12-00855}
--------------------------

One of the important electrical properties of AgNPs in a colloidal suspension is zeta potential which is influenced by the size of the NPs. AgNPs possess a large absolute value of zeta potential corresponding to a high surface electrical charge which can result in a strong repulsive force among particles to resist agglomeration \[[@B41-cancers-12-00855]\]. Agglomeration needs to be suppressed at any cost to prevent the growth of the particles from nanoscale to microscale. It has been established that a high zeta potential value of around −25 mV ensures a large enough energy barrier for the stabilization of the nanosuspension. For example, Sankar et al. reported a zeta potential of about −26 ± 0.77 mV for the biosynthesis of AgNPs with an average size of 136 ± 10.09 nm from *Origanum vulgare* \[[@B42-cancers-12-00855]\].

3. Biologic Synthesis of AgNPs {#sec3-cancers-12-00855}
==============================

Both "top-down" and "bottom-up" approaches can be adopted for NPs synthesis, including AgNPs \[[@B43-cancers-12-00855]\]. A top-down approach involves reducing particle size of an appropriate starting material until NPs are obtained. Different physical and chemical processes like ball milling, chemical etching, laser ablation and sputtering are known top-down approaches \[[@B44-cancers-12-00855]\]. However, a major drawback of top-down approaches is the occurrence of surface defects on the NPs \[[@B45-cancers-12-00855]\]. Conversely, a bottom-up approach produces NPs by assembling smaller entities like atoms, molecules or particles to assemble the NPs \[[@B46-cancers-12-00855]\]. Bottom-up methods are typically chemical or biologic in nature (e.g., sol-gel processes, spray pyrolysis, electrochemical precipitation and laser pyrolysis) \[[@B47-cancers-12-00855]\].

The downside of most AgNPs synthesis protocols involving chemical and physical methods include associated high cost and the use of toxic and potentially hazardous materials which may pose environmental and biologic threats ([Figure 1](#cancers-12-00855-f001){ref-type="fig"}). NPs produced through chemical synthesis are often not suitable for medical applications because of toxic substances absorbed onto the NPs surfaces. Commercial AgNPs have to be handled and must be cost-effective for practical purposes. Therefore, alternative synthetic methods are required that are environmentally sound and economically feasible. The pursuit of such methods has led to the investigation of biologic processes for synthesis \[[@B48-cancers-12-00855]\]. In biologic synthesis of AgNPs, molecules produced by living organisms (e.g., bacteria, fungi or plants), act as reducing and stabilizing agents \[[@B49-cancers-12-00855]\]. The microbial enzymes or the plant phytochemicals possessing antioxidant or reducing properties are mainly responsible for NP biologic synthesis \[[@B50-cancers-12-00855]\].

3.1. Bacterial Synthesis of AgNPs {#sec3dot1-cancers-12-00855}
---------------------------------

Biosynthesis of NPs may occur extracellularly or intracellularly. A widely utilized extracellular mechanism for AgNPs synthesis via bacteria employs NADH-dependent nitrate reductase-mediated reduction of silver ion (Ag^+^) by several bacteria species, such as *Streptomyces* sp. LK3 \[[@B51-cancers-12-00855]\] and *Bacillus licheniformis* \[[@B52-cancers-12-00855]\]. During reduction, nitrate ions (NO~3~^−^) in silver nitrate (AgNO~3~) are reduced to nitrite (NO~2~^−^) by accepting two protons then releasing two electrons and water. Electrons released in this reaction are transferred to the Ag^+^ ion to form elemental silver (Ag^0^) \[[@B53-cancers-12-00855]\]. This mechanism is possibly dependent on electron transport pathways and enzymatic metal reduction processes ([Figure 2](#cancers-12-00855-f002){ref-type="fig"}).

However, enzymes are not always necessary for bacterial synthesis of AgNPs. For example, non-enzymatic intracellular synthesis was reported in *Lactobacillus* A09, where Ag^+^ reduction occurred on the bacterial cell surface \[[@B53-cancers-12-00855]\]. Gram-positive bacterial cell walls, such as those of *Lactobacillus* A09, contain numerous anionic surface groups. These groups can provide silver ion biosorption sites \[[@B55-cancers-12-00855]\]. The pH of the surrounding medium decreased slightly after adsorption of Ag^+^ on *Lactobacillus* A09, suggesting competition between proton and silver ion binding to negatively charged sites \[[@B56-cancers-12-00855]\]. Potentially an increase in pH can open bacteria cell wall monosaccharide rings and oxidize these moieties to open-chain aldehydes. At the same time, dissociation of protons from protonated anionic functional groups (--RH) creates negatively charged Ag^+^ adsorption sites on the cell surface. The two electron released while forming the aldehyde group from an alcohol can reduce Ag^+^ ions to elemental Ag^0^ \[[@B57-cancers-12-00855]\]. The steps involved in the bacterial synthesis of AgNPs are mediated through glucose ring-opening ([Figure 3](#cancers-12-00855-f003){ref-type="fig"}).

3.2. Fungal Synthesis of AgNPs {#sec3dot2-cancers-12-00855}
------------------------------

Due to their inherent ability to efficiently secrete protein, fungi can produce substantially larger amounts of AgNPs than bacteria \[[@B58-cancers-12-00855]\]. However, the exact mechanism by which fungi synthesize AgNPs is not completely understood. Mukherjee et al. hypothesized that the following steps may occur during synthesis in *Verticillium* model system: Ag^+^ ions interact electrostatically with negatively charged carboxylate groups in the mycelial cell wall and are trapped at the cell surface. Subsequently, trapped ions are reduced by specific fungal enzymes \[[@B46-cancers-12-00855]\]. Enzymes involved in fungal NP synthesis are generally reductases \[[@B59-cancers-12-00855]\]. For example, during synthesis of AgNPs by *Aspergillus flavus*, a 32-kDa reductase protein secreted by the fungal isolate, reduces Ag^+^ ions \[[@B60-cancers-12-00855]\]. A schematic representation of AgNPs synthesis by fungi is presented in [Figure 4](#cancers-12-00855-f004){ref-type="fig"}.

3.3. Plant Synthesis of AgNPs {#sec3dot3-cancers-12-00855}
-----------------------------

Plant extracts have been used for AgNPs synthesis and can be superior to bacterial and fungal synthetic systems due to their availability, low toxicity and safety. A wide range of extracted phytochemicals can rapidly reduce silver ions. Reduction can be rapid compared to microbial fermentation \[[@B50-cancers-12-00855]\], as this approach can avoid lengthy sterile cell-culture under controlled conditions \[[@B61-cancers-12-00855]\]. Furthermore, plant extracts can act as both reducing and stabilizing agent during AgNPs synthesis. Approaches of reduction with plant extracts can be applied to other metallic NPs \[[@B62-cancers-12-00855]\]. The plant source determines the properties of the AgNPs \[[@B63-cancers-12-00855]\]. The concentration of individual phytochemicals and combinations of phytochemicals present vary considerably in extracts depending on the plant source. Therefore, AgNPs' properties can be selected by controlling the extract composition \[[@B64-cancers-12-00855]\]. The biosynthesis of AgNPs by plant extracts commonly involves mixing of an aqueous solution of silver nitrate with an aqueous plant extract. Typical reactions take place at room temperature and requires only a few minutes to complete \[[@B47-cancers-12-00855]\].

Numerous phytochemicals have been identified that are capable of producing AgNPs. As examples, flavonoids, terpenoids, terpenes, flavones, phenolics, polysaccharides, saponins, tannins and alkaloids have all been used for AgNPs synthesis \[[@B47-cancers-12-00855],[@B65-cancers-12-00855]\]. Phytochemical functional groups, such as hydroxyl, aldehyde, ketone, carboxyl and amino groups are capable of reducing Ag^+^ ions \[[@B50-cancers-12-00855],[@B66-cancers-12-00855]\]. Due to the diversity of phytochemicals the exact mechanism of AgNPs synthesis varies. However, the chief mechanism is the reduction of Ag^+^ ions by specific functional groups. For example, *Punica granatum* peel extract contains the flavonoids- kaempferol and naringin along with their glycosides. All of these compounds have hydroxyl (--OH) groups that cause the reduction of the Ag^+^ ions, resulting in the formation of AgNPs \[[@B67-cancers-12-00855]\]. A typical reduction is possible by the use of kaempferol as a reducing agent ([Figure 5](#cancers-12-00855-f005){ref-type="fig"}).

Interestingly, not all phytochemicals present in plant extracts capable of reducing other compounds remain active during Ag^+^ ions reduction and only certain phytochemicals are involved in this reduction. For example, phytochemical screening revealed the presence of phenols, glycosides, flavonoids, reducing sugars, resins, tannins, terpenoids, steroids, alkaloids and saponins in *Anagallis tenella* leaf extract ([Table 1](#cancers-12-00855-t001){ref-type="table"}).

However, it was discovered that only flavonoids were involved in AgNPs synthesis \[[@B65-cancers-12-00855]\]. Active phytochemicals associated with AgNPs synthesis in other plants are listed in [Table 1](#cancers-12-00855-t001){ref-type="table"}. As stated earlier, the wide variety of phytochemicals present in different plants that contribute to AgNPs synthesis complicates this field of study. Each plant has a unique spectrum of phytochemicals that act as organic reducing agents \[[@B72-cancers-12-00855]\].

4. AgNPs Characterization {#sec4-cancers-12-00855}
=========================

Ultraviolet-visible (UV-Vis) spectroscopy, dynamic light scattering (DLS), scanning electron microscopy (SEM), transmission electron microscopy (TEM), Fourier-transform infrared spectroscopy (FTIR), thermogravimetric analysis (TGA), X-ray diffraction (XRD) and energy dispersive spectroscopy (EDS) are commonly used for AgNP characterization \[[@B75-cancers-12-00855],[@B76-cancers-12-00855]\].

UV-Vis light spectroscopy is used to determine AgNPs formation by measuring the optical absorbance spectra. The wavelength of the light absorbed is heavily affected by the size and aspect ratio of these NPs. Variations in sizes cause each solution to have a different color. The vibrant colors occur because the conduction electrons on the surface of each nanoparticle vibrate when a particular wavelength of light excites them ("surface plasmon resonance" phenomenon as discussed earlier). These vibrations result in extremely bright colors which can be tweaked by altering the particle size and shape. In case of spherical NPs, the larger they are, the "bluer" they appear. The color change results from the interaction of the individual metal atoms with each other \[[@B77-cancers-12-00855]\].

DLS is a technique that can be utilized to determine particle size and particle size distribution \[[@B78-cancers-12-00855]\]. Since the range of size DLS is capable of measuring is a few nanometers to a few micrometers, it is a suitable method for measuring the size of AgNPs. This method operates by calculating the change in the light frequency while interacting with the particles of varying size. The smaller the particles are, the greater is the shift in the light frequency \[[@B79-cancers-12-00855]\].

SEM and TEM can be utilized to characterize AgNPs shape and morphology \[[@B80-cancers-12-00855]\]. It has been demonstrated that mostly spherically shaped NPs are detected by electron microscopy in case of plant-mediated AgNPs \[[@B81-cancers-12-00855]\]. TEM has a thousand-fold higher resolution than SEM but SEM images have superior depth of field \[[@B82-cancers-12-00855]\]. These two modes of electron microscopy are complementary to each other.

FTIR spectroscopy has been used to characterize AgNPs surface chemistry, i.e., the functional groups present on NPs surfaces can be identified with the help of this technique \[[@B83-cancers-12-00855]\]. The surface-bound functional groups illustrate the capping and reducing agents involved in AgNPs biosynthesis. Identifying the type of capping agent is vital because the type of capping agent regulates the efficacy of the AgNPs \[[@B84-cancers-12-00855]\]. The capping agents can stabilize the AgNPs by preventing the agglomeration of the particles. In addition, they inhibit the interactions of the particles with in vivo components and restores their activities \[[@B40-cancers-12-00855]\]. In the FTIR analysis spectra, major peaks are identified; each peak corresponds to a specific functional group. For example, the prominent peak at 3348 cm^−1^ is attributed to O--H stretching, whereas the peaks at 2974 and 2887 cm^−1^ correspond to C--H stretching vibrations of methyl, methylene or methoxy groups. The other noticeable peaks positioned at 1656 and 420 cm^−1^ are attributed to the C=O stretching in carbonyl group, while the peak at 1049 cm^−1^ is attributed to the C=O stretching of the alcoholic group \[[@B85-cancers-12-00855]\].

The types of bio-organic compounds or functional groups on the AgNPs surfaces can be further confirmed by TGA analysis. TGA identifies the organic compounds on the NPs surfaces by determining the thermal stability of the compounds. TGA detects the characteristic weight losses at certain ranges of temperatures which is attributes to specific compounds on the AgNPs surfaces. For example, Kajani et al. reported that the weight loss of AgNPs synthesized using ethanolic extract of *T. baccata* was 27% when the temperature of the sample was raised from 0--521 °C. Another weight loss of 8.3% followed when the temperature reached 678 °C. The final result was a total weight loss of about 36.89% after increasing the temperature up to 700 °C \[[@B40-cancers-12-00855]\].

Phase identification and crystal structure determination of NPs can be determined by X-ray diffraction of monochromatic collimated X-rays (XRD) by NPs \[[@B86-cancers-12-00855]\]. With the help of XRD, the presence of AgNPs in the synthesis product can be confirmed. The confirmation takes place by identifying the peaks in the XRD spectrum characteristic of the face centered cubic crystal structure of metallic silver. The diffraction peak values at 38.39°, 44.53°, 64.13° and 77.59° are referred to (111), (200), (220) and (311) lattice planes, respectively of metallic silver. Moreover, the average grain size of the AgNPs can be computed from the X-ray diffraction (XRD) analysis by using Scherer equation shown below: $$D = \frac{K\lambda}{\beta cos\theta}$$ where '*D*' is the particle diameter size, '*K*' is a constant, '*λ*' is the wavelength of X-ray source, '*β*' is the full width half maximum (FWHM) and '$\theta$' is the diffraction angle \[[@B85-cancers-12-00855]\].

Elemental analysis of NPs can be performed by EDS \[[@B87-cancers-12-00855]\]. In the case of AgNPs, the energy dispersive spectroscopy (EDS) profile displays a strong signal corresponding to silver fluorescence. However, fluorescence from other elements, such as carbon and oxygen---originating from biomolecules attached to the AgNPs---can also appear \[[@B81-cancers-12-00855]\].

5. Biosynthesized AgNPs as Anticancer Agents in Vitro {#sec5-cancers-12-00855}
=====================================================

Optimal procedures for anti-cancer AgNPs preparation are broadly being examined. It is worth mentioning that we have noted some biosynthesized AgNPs from bacterial and fungal sources in the [Table S1](#app1-cancers-12-00855){ref-type="app"} to keep the review less verbose. However, AgNPs synthesized with the contribution of biologic sources displayed significant inhibitory activities against the viability of certain cancerous cell lines. In those processes, for example, the bio-extracts collected from different plant parts (e.g., leaf, root, flower or fruit) were used as reducing agents.

Literature searches have uncovered studies of 23 plant extracts which were used for AgNPs preparation. Many of these AgNPs were either toxic to the breast cancer cell line MCF-7 or inhibited its growth. The sizes of NPs reported in these studies ranged from 5--80 nm; their shapes also varied (e.g., spherical, cuboidal, pentagonal and hexagonal). The IC~50~ values of these extracts against Michigan Cancer Foundation (MCF)-7 cells ranged from 3.04--250 μg/mL ([Table 2](#cancers-12-00855-t002){ref-type="table"}). Moreover, some research outcomes showed that the half maximal inhibitory concentration (IC~50~) of AgNPs was dependent upon the dose of the extract given \[[@B40-cancers-12-00855],[@B65-cancers-12-00855],[@B75-cancers-12-00855],[@B85-cancers-12-00855],[@B88-cancers-12-00855],[@B89-cancers-12-00855],[@B90-cancers-12-00855],[@B91-cancers-12-00855],[@B92-cancers-12-00855],[@B93-cancers-12-00855],[@B94-cancers-12-00855],[@B95-cancers-12-00855],[@B96-cancers-12-00855],[@B97-cancers-12-00855],[@B98-cancers-12-00855],[@B99-cancers-12-00855],[@B100-cancers-12-00855],[@B101-cancers-12-00855],[@B102-cancers-12-00855],[@B103-cancers-12-00855],[@B104-cancers-12-00855]\]. Data regarding the breast cancer cell line MCF-7 cells are enumerated in [Table 3](#cancers-12-00855-t003){ref-type="table"} with citations.

Biosynthesized AgNPs have also been found to inhibit the brain cancer cell line HNGC2 \[[@B88-cancers-12-00855]\]. These spherical AgNPs ranged in size from 20--80 nm, and the IC~50~ values were dose-dependent \[[@B101-cancers-12-00855]\]. Biosynthesized AgNPs have also shown notable inhibitory activity against the cervical cancer cell lines Siha and HeLa. Growth of the Siha cancer cell line was inhibited by 2--18 nm triangular and hexagonal AgNPs, with an IC~50~ of ≤4.25 μg/mL \[[@B106-cancers-12-00855]\]. In contrast, spherically shaped AgNPs, with sizes ranging between 5--120 nm, achieved inhibitory effects on HeLa cancer cell lines. The IC~50~ values varied depending on the preparation method of the AgNPs and also depended upon the plant extracts used \[[@B23-cancers-12-00855],[@B25-cancers-12-00855],[@B95-cancers-12-00855],[@B107-cancers-12-00855],[@B108-cancers-12-00855],[@B109-cancers-12-00855],[@B110-cancers-12-00855],[@B111-cancers-12-00855],[@B112-cancers-12-00855]\]. The bio-synthesized AgNPs, inhibited four colon cancer cell lines (e.g., COLO 205, HCT 15, HCT-116 and HT29 cells), with IC~50~ values ranging from 5.5--100 μg/mL \[[@B61-cancers-12-00855],[@B103-cancers-12-00855],[@B105-cancers-12-00855],[@B113-cancers-12-00855],[@B114-cancers-12-00855],[@B115-cancers-12-00855],[@B116-cancers-12-00855]\]. The particles were substantially spherical in shape, with sizes ranging from 7.39--80 nm. Available data regarding these AgNPs in the context of brain, cervical and colon cancers are represented in [Table 3](#cancers-12-00855-t003){ref-type="table"}.

Cuboidal and spherical bio-AgNPs with sizes ranging from 59--94 nm, prepared from different plant extracts, inhibited the A431 cell line, an epidermoid carcinoma, with IC~50~ values ranging from 78.58--83.57 μg/mL \[[@B117-cancers-12-00855]\]. Inhibition by bio-extract-derived spherical AgNPs with sizes ranging from 5--50 nm was also observed against the AGS cell line, a gastric carcinoma, with an IC~50~ of 21.05 μg/mL \[[@B118-cancers-12-00855]\]. A hepatic cancer cell line (Hep-G2) was inhibited by spherical AgNPs that ranged in size from 6.4--1200 nm. In those studies, the results were presented according to different parameters; IC~50~ values ranged from 10.02 to more than 30 μg/mL, the load of detection was 31.25 ng/mL, there was 13.86% viability at 25 μL, and some of the other results demonstrated a dose dependent relationship \[[@B75-cancers-12-00855],[@B89-cancers-12-00855],[@B97-cancers-12-00855],[@B119-cancers-12-00855],[@B120-cancers-12-00855]\]. Spherical bio-AgNPs that were less than 20 nm in size inhibited the Caco-2 intestinal cancer cell line, where the IC~50~ value was greater than 30 μg/mL. Biosynthesized, spherical AgNPs with sizes less than 40 nm blocked the Hek-293 kidney cancer cell line in a dose-dependent manner \[[@B95-cancers-12-00855],[@B98-cancers-12-00855]\]. The 31-nm, spherical, green AgNPs repressed the Hep-2 laryngeal carcinoma cell line, with IC~50~ values of 3.42 μg/mL and 12.5 μg/mL, and an AgNPs concentration of 500 nM \[[@B105-cancers-12-00855],[@B121-cancers-12-00855],[@B122-cancers-12-00855]\]. The H1299 and HL-60 leukemia cell lines were inhibited by 8--22 nm spherical bio-AgNPs with an IC~50~ value of 5.33 μg/mL and in a dose-dependent manner, respectively \[[@B112-cancers-12-00855],[@B123-cancers-12-00855]\]. The data related to epidermoid carcinoma, laryngeal carcinoma, gastronomic carcinoma, hepatic cancer, intestinal cancer and kidney cancer are enumerated in [Table 4](#cancers-12-00855-t004){ref-type="table"}.

According to a literature review, 13 bio-extracts have been successfully used as reducing agents to prepare AgNPs that can block the activities of the A549 lung cancer cell line \[[@B42-cancers-12-00855],[@B75-cancers-12-00855],[@B89-cancers-12-00855],[@B101-cancers-12-00855],[@B104-cancers-12-00855],[@B125-cancers-12-00855],[@B126-cancers-12-00855],[@B127-cancers-12-00855],[@B128-cancers-12-00855],[@B129-cancers-12-00855],[@B130-cancers-12-00855],[@B131-cancers-12-00855]\]. The size of those spherically shaped NPs ranged from 13--136 nm, and the inhibitory actions were observed to follow a dose-dependent relationship, with various IC~50~ and LD~50~ values as mentioned below \[[@B42-cancers-12-00855],[@B75-cancers-12-00855],[@B89-cancers-12-00855],[@B101-cancers-12-00855],[@B104-cancers-12-00855],[@B125-cancers-12-00855],[@B126-cancers-12-00855],[@B127-cancers-12-00855],[@B128-cancers-12-00855],[@B129-cancers-12-00855],[@B130-cancers-12-00855],[@B131-cancers-12-00855]\]. The spherical bio-AgNPs with sizes ranging from 5--50 nm showed inhibitory activities against the lymphoma Jurkat cell line, and the IC~50~ was 21.05 μg/mL \[[@B132-cancers-12-00855]\]. The B16F10 melanoma cell line was inhibited by the 20--228 nm spherical bio-AgNPs, with an IC~50~ value of 7.6 ± 0.8 μg/mL, following a dose-dependent relationship \[[@B101-cancers-12-00855],[@B133-cancers-12-00855]\]. The 100--120 nm flower-shaped AgNPs exhibited notable repressive actions against the KB oral cancer cell line, where the IC~50~ was 0.6 μg/mL \[[@B134-cancers-12-00855]\]. The 15--32 nm spherical bio-AgNPs impeded the PA1 ovarian cancer cell line, with an IC~50~ value of 7.5 μg/mL and in a dose-dependent manner \[[@B125-cancers-12-00855],[@B127-cancers-12-00855]\]. Inhibitory activities were observed against the BxPC 3 pancreatic cancer cell line by spherical bio-AgNPs with sizes ranging from 8--22 nm, and the IC~50~ was 38.9 μg/mL \[[@B123-cancers-12-00855]\]. The 9--99 nm and 8--22 nm spherical AgNPs repressed the PC3 and VCaP prostate cancer cell lines, respectively, in dose-dependent manners with IC~50~ values ranging from 6.85--87.33 μg/mL \[[@B76-cancers-12-00855],[@B123-cancers-12-00855],[@B135-cancers-12-00855]\]. All of these data regarding the cell lines mentioned above for lung cancer, lymphoma, melanoma, oral cancer, ovarian cancer, pancreatic cancer and prostate cancer are summarized in [Table 5](#cancers-12-00855-t005){ref-type="table"} with appropriate citations.

6. Anticancer Mechanism of Biosynthesized AgNPs {#sec6-cancers-12-00855}
===============================================

The cytotoxicity of AgNPs depends upon their size and shape. For example, it was reported that AgNPs with diameters of 100--160 nm, lengths of 1.5--25 μm, and spherical shapes (30 nm) showed potential cytotoxic effects on human lung epithelial A549 cells \[[@B42-cancers-12-00855]\]. The most probable reason for this is that within this size and shape range, the AgNPs can directly contact the cell surfaces and initiate cytotoxicity \[[@B137-cancers-12-00855]\]. NPs are safe at lower dose and can be toxic at higher dose. Usually cells treated with various NPs concentration show a dose-dependent increase in cell inhibition. AgNPs in different formulations exhibit variable dose effects that may affect the cytotoxicity or improve the anticancer activity. Many reports demonstrated the anticancer activity of AgNPs synthesized by biosynthetic routes. Nevertheless, AgNPs synthesized by biosynthesis also show sort of cytotoxicity \[[@B138-cancers-12-00855],[@B139-cancers-12-00855]\]. The sizes and shapes of the different AgNPs reviewed in this manuscript are summarized in [Table 2](#cancers-12-00855-t002){ref-type="table"}, [Table 3](#cancers-12-00855-t003){ref-type="table"}, [Table 4](#cancers-12-00855-t004){ref-type="table"} and [Table 5](#cancers-12-00855-t005){ref-type="table"}. Furthermore, most of the NPs that were synthesized from plant sources were spherical in shape and demonstrated significant efficacy against cancer cell lines ([Table 2](#cancers-12-00855-t002){ref-type="table"}, [Table 3](#cancers-12-00855-t003){ref-type="table"}, [Table 4](#cancers-12-00855-t004){ref-type="table"} and [Table 5](#cancers-12-00855-t005){ref-type="table"}).

Blood vessels play a vital role in supplying nutrients and clearing waste products at the tissue level; the formation of new blood vessels from existing vessels is termed angiogenesis. Wound healing and granulation tissue formation are some potential results of angiogenesis \[[@B140-cancers-12-00855]\]. According to Folkman's hypothesis, the growth of solid tumors is the result of new blood vessel formation \[[@B141-cancers-12-00855]\]. This process is thought to play a pivotal role in the growth and spread of cancer and is regulated by both activator and inhibitor molecules. According to this hypothesis, blood supply is necessary for the growth of tumors. The new blood vessels contribute to tumor growth by supplying oxygen and nutrients to cancer cells helping them to invade and spread throughout the body; this phenomenon is known as metastasis \[[@B142-cancers-12-00855]\]. Recent studies have suggested that green-synthesized AgNPs displayed efficacy in treating retinal neovascularization (RNV)-like diseases. They inhibited vascular endothelial growth factor-induced RNV and blocked extracellular signal-related kinase (ERK½) activation via regulation of vascular endothelial growth factor receptor-2 phosphorylation. These anti-angiogenesis properties have been applied in cancer treatment using different approaches of AgNPs \[[@B143-cancers-12-00855]\]. Interestingly, Rekha Khandia and her team successfully reduced the angiogenesis in embryonated chicken mode ([Figure 6](#cancers-12-00855-f006){ref-type="fig"}).

The cell cycle incorporates a complex series of signaling pathways, by which a cell grows replicates its DNA and divides. This phenomenon plays a vital role in cancer progression. However, due to the genetic mutations that occur in cancer, this regulatory process malfunctions, which leads to uncontrolled cell proliferation. DNA synthesis (S), Gap2/mitosis (G2/M), Gap1 (G0/G1) and subG1 are all vital checkpoints for cell cycle arrest \[[@B145-cancers-12-00855]\] in [Figure 7](#cancers-12-00855-f007){ref-type="fig"}. Different studies have suggested that green-synthesized AgNPs can arrest the sub-G1 phase of the cell cycle. Chang et al. revealed that the sub-G1 phase was arrested in curcumin-treated cancer cells, which explains the direct correlation between the sub-G1 phase arrest of cancerous cells and apoptosis \[[@B146-cancers-12-00855]\]. Another study demonstrated the connection between an increased cancer cell population in the sub-G1 phase and expression of the pro-apoptotic protease caspase-3 \[[@B147-cancers-12-00855]\].

7. Toxicity {#sec7-cancers-12-00855}
===========

The toxicity of AgNPs has been mentioned in different studies; Bharadwaj Punita reported that AgNPs could be highly toxic to mammalian cells, e.g., brain cells, liver cells and stem cells \[[@B148-cancers-12-00855]\]. Besides, Mahmoudi and his team stated that the AgNPs are highly toxic to healthy/normal cells \[[@B149-cancers-12-00855]\]. Conversion of metal into its nano-form may bring the risk of toxicity. However, the green synthesis method reduces the toxicity of AgNPs. The nominal toxicity mainly depends upon its coating. The coating of AgNPs stabilize the particles and prevent their agglomeration. Here, the biocompatible behavior of coating makes green synthesized AgNPs suitable for numerous medicinal applications \[[@B150-cancers-12-00855]\].

8. Inter-Connection between Antimicrobial Property and Anticancer Activity of AgNPs {#sec8-cancers-12-00855}
===================================================================================

Studies have revealed that the mitochondrial activation and reactive oxygen species (ROS) overproduction are the key factors of AgNPs in antimicrobial and anticancer defense. Interestingly, the ROS production and the subsequent damages resulting from oxidative stress are AgNPs size-dependent, smaller NPs cause better ROS overproduction \[[@B151-cancers-12-00855]\]. AgNPs can induce mitochondrial chain and complex disruption which lead to superoxide anion leakage \[[@B152-cancers-12-00855],[@B153-cancers-12-00855]\]. Here, Ag+ ions are released that can influence the mitochondrial enzymes and also interact with --SH groups of proteins and glutathione (GSH). Because of this situation, the ROS scavenging potential of GSH decreases and oxidative stress takes place \[[@B154-cancers-12-00855]\]. DNA damage could change the gene expression, and cellular death may be exhibited as apoptosis \[[@B153-cancers-12-00855],[@B154-cancers-12-00855]\].

9. Clinical Application {#sec9-cancers-12-00855}
=======================

AgNPs have been investigated intensively regarding their promising anticancer effects exhibited in different human cancer cell lines, such as endothelial cells, IMR-90 lung fibroblasts, U251 glioblastoma cells and MDA-MB-231 breast cancer cells \[[@B40-cancers-12-00855],[@B106-cancers-12-00855],[@B155-cancers-12-00855],[@B156-cancers-12-00855]\]. AgNPs showed great promises as effective anti-tumor drug-delivery systems \[[@B157-cancers-12-00855]\]. As previously mentioned, conventional cancer treatments such as chemotherapy, radiotherapy or surgery have their limitations associated with drug toxicity, unpredictable side effects, drug resistance problems and lack of specificity. AgNPs overcome these disadvantages by reducing the side effects and enhancing the efficiency of cancer therapy. One of their distinguishing features is the ability to cross various biologic barriers and to provide targeted delivery of drugs. Green synthesis of AgNPs together with specific delivery of anticancer drugs to tumor tissues offers an innovative approach for improving cancer treatment. Currently, theranostics approach (the combination of therapy and diagnosis) is one of the most attractive and challenging approaches, which is effective in personalized therapy for cancer treatment. As mentioned in [Section 2.2](#sec2dot2-cancers-12-00855){ref-type="sec"}, AgNPs are plasmonic structures, particularly capable of scattering and absorbing the lights impinging certain areas. After their selective uptake into cancerous cells, AgNPs-derived scattered lights can be used for imaging purposes. Silver has been used for centuries in dental care as a major component of amalgams used for tooth restoration. However, AgNPs proved to be efficient agents in dental practice; nevertheless, they remain controversial candidates due to their variable toxicity in biologic systems \[[@B158-cancers-12-00855]\]. Interestingly, AgNPs showed promising activity against both the malarial parasite (*Plasmodium falciparum*) and its related vector (*Anopheles* female mosquito) \[[@B159-cancers-12-00855]\].

Bioavailability of AgNPs is low in oral, dermal and inhalational exposures, however, it depends on the particle size, dose, surface coating and soluble fraction. For examples, Park and his team revealed that in a single oral exposure in rats, the bioavailability of citrate-coated 7.9 nm AgNPs was 1.2% and 4.2% in the 1 and 10 mg/kg, respectively \[[@B160-cancers-12-00855]\]. After oral exposure, AgNPs can be ionized to form Ag+ in the stomach, but the dissolution is incomplete due to the limited gastric residence time (10--240 min). Ag^+^ and other soluble complexes like AgCl(aq) and AgCl~2~^−^ can be absorbed by the gastrointestinal tract into the systemic circulation, where Ag+ can bind to proteins with thiol groups such as serum albumin and small thiol molecules like glutathione (GSH). These complexes generate H+ and GS-Ag which then produce Ag-GSH complexes that are distributed throughout the body. However, biliary pathway is the major elimination route for AgNPs \[[@B161-cancers-12-00855]\].

10. Future of AgNPs {#sec10-cancers-12-00855}
===================

Despite all the recent advancements in cancer treatment, cancer remains one of the most common causes of death around the globe. It is already known to us that the conventional treatment strategies often have many side effects of their own. Therefore, scientists are looking to design novel strategies for the diagnosis and treatment of cancer. Recently, green synthesis of AgNPs has gained much attention in the pharmaceutical field. The use of green chemistry is non-toxic, cheap and environmentally friendly, although there are some disadvantages of biologic methods as listed in [Box 1](#cancers-12-00855-box001){ref-type="boxed-text"}. The high biodegradability and clearance of AgNPs also play a pivotal role in avoiding the potential effect of long-term toxicity. The AgNPs showed great promises in cases of nanomedicine-based treatment. However, clinical trials of AgNPs-based nanomedicine are necessary for guiding the future direction of their application. Currently, investigations into the biodegradability, dose and route of administration are the major hurdles that need to be tackled in clinical trials. Moreover, AgNPs can be used as a vital cancer cell visualization and detection tool in diagnosing cancer at its early stages \[[@B162-cancers-12-00855]\]. It has already been shown that green synthesis of AgNPs can help with in vivo fluorescent tumor imaging \[[@B123-cancers-12-00855]\]. We believe that green-synthesized AgNPs will be used as potential cancer therapeutics and diagnostics agents in the upcoming era of cancer treatment.

###### Advantages and disadvantages of green synthesis methods.

Advantages of biologic methods: These methods are inexpensive, eco-friendly and non-toxic.No complex setup is required to conduct the synthesis process.It is not necessary to use stabilizing agents to prevent agglomeration of the NPs.Since these processes are carried out in ambient conditions, they are not energy intensive.These methods offer finer tuned control of the size and shape of the NPs compared to chemical and physical methods.

Disadvantages of biologic methods: Synthesis by biologic methods is not as fast as synthesis by chemical methods.Because of the presence of numerous biomolecules present in the biologic sources, it is difficult to pinpoint the exact biomolecules responsible for the synthesis of the NPs.If the biologic synthesis is conducted on a large scale, an ecological imbalance may kick in from overuse of different biologic species.Microbe toxins may be brought together by biologic synthesis.

11. Conclusions {#sec11-cancers-12-00855}
===============

Business experts have extrapolated that the global market of nanotechnology has a potentially bright future. Commercially produced AgNPs are being manufactured at a significantly large scale and the application of NPs as therapeutic agents is increasing. AgNPs are promising drug leads based on the successful results of previous research studies as well as their cost. However, there are some basic hindrances to using the AgNPs as therapeutic agents in terms of toxicity. To overcome these hindrances---and for use in preclinical trials on humans or any other living bodies---the AgNPs should be biocompatible, non-toxic and free from side effects. Finally, usage of biogenic AgNPs as cancer nanomedicine will require elaborate datasets that uncover potential toxicity and pharmacological issues such as the side effects.
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![Synthesis of AgNPs by reaction of AgNO~3~ with phytochemicals (concept of this representation was based on \[[@B67-cancers-12-00855]\]).](cancers-12-00855-g005){#cancers-12-00855-f005}

![AgNPs were evaluated for their effects on the process of angiogenesis in a chicken embryonic chorioallantoic membrane model. (**A**) control egg, (**B**) microscopic view of A, (**C**) egg treated with AgNPs, (**D**) microscopic view of (**C**) (Adapted from Khandia et al. with permission \[[@B144-cancers-12-00855]\]).](cancers-12-00855-g006){#cancers-12-00855-f006}

![Schematic diagram of cell cycle arrest by AgNPs.](cancers-12-00855-g007){#cancers-12-00855-f007}

cancers-12-00855-t001_Table 1

###### 

Active phytochemical fractions associated with AgNPs synthesis in specific plants.

  Plant                   Phytochemical                                                                            Reference
  ----------------------- ---------------------------------------------------------------------------------------- -----------------------------
  Alternanthera tenella   Flavonoids                                                                               \[[@B65-cancers-12-00855]\]
  Cocos nucifera          Carbohydrates, alkaloids, terpenoids, tannins, saponins, phenolics and reducing sugars   \[[@B68-cancers-12-00855]\]
  Lemongrass              Reducing sugars                                                                          \[[@B69-cancers-12-00855]\]
  Ocimum sanctum          Caffeine                                                                                 \[[@B70-cancers-12-00855]\]
  Chrysanthemum indicum   Tannins, flavonoids and glycosides                                                       \[[@B71-cancers-12-00855]\]
  Dalbergia spinose       Reducing sugars and flavonoids                                                           \[[@B72-cancers-12-00855]\]
  Cinnamomum camphora     Phenolics, terpenoids, polysaccharides and flavones                                      \[[@B73-cancers-12-00855]\]
  Eucalyptus hybrid       Flavonoids and terpenoids                                                                \[[@B74-cancers-12-00855]\]

cancers-12-00855-t002_Table 2

###### 

Studies AgNPs from plants that inhibit the breast cancer cell line MCF-7.

  Plant                                   Part Used            NP Size/NP Shape                                    Incubation Time   IC~50~                         Ref.
  --------------------------------------- -------------------- --------------------------------------------------- ----------------- ------------------------------ ------------------------------
  *Achillea biebersteinii*                Flower               12 nm/spherical, pentagonal                         3 h               20 μg/mL                       \[[@B88-cancers-12-00855]\]
  *Alternanthera sessilis*                Aerial parts         10--30 nm/spherical                                 6 h               3.04 μg/mL                     \[[@B94-cancers-12-00855]\]
  *Alternanthera tenella*                 Leaf                 About 48 nm/-                                       \-                42.5 μg/mL                     \[[@B65-cancers-12-00855]\]
  *Andrographis echioides*                Leaf                 68.06 nm/cubic, pentagonal, hexagonal               12 h              31.5 μg/mL                     \[[@B91-cancers-12-00855]\]
  *Azadirachta indica*                    Leaf                 \<40 nm/spherical                                   6 h               Dose dependent                 \[[@B95-cancers-12-00855]\]
  *Butea monosperma*                      Leaf                 20--80 nm/spherical                                 2 h               Dose dependent                 \[[@B101-cancers-12-00855]\]
  *Coriandrum sativum*                    Leaf                 About 37 nm/spherical, rod, triangular, hexagonal   \-                30.5 μg/mL                     \[[@B97-cancers-12-00855]\]
  *Citrullus colocynthis*                 Leaf                 13.37 nm/spherical                                  24 h              \>30 μg/mL                     \[[@B103-cancers-12-00855]\]
  Roots                                   7.39 nm/spherical    24 h                                                2.4 μg/mL                                        
  Seeds                                   16.57 nm/spherical   24 h                                                \>30 μg/mL                                       
  Fruit                                   19.26 nm/spherical   24 h                                                \>30 μg/mL                                       
  *Dendrophthoe falcata (L.f) Ettingsh*   Mistletoe, leaf      5--45 nm/spherical                                  24 h              Dose dependent                 \[[@B100-cancers-12-00855]\]
  *Erythrina indica*                      Root                 20--118 nm/spherical                                Overnight         23.89 (% viability at 25 μL)   \[[@B75-cancers-12-00855]\]
  *Melia dubia*                           Leaf                 7.3 nm/irregular                                    15 min            31.2 μg/mL                     \[[@B85-cancers-12-00855]\]
  *Olax scandens*                         Leaf                 30--60 nm/spherical                                 2 h               Dose dependent                 \[[@B96-cancers-12-00855]\]
  *Panax ginseng*                         Leaf                 \-                                                  \-                Dose dependent                 \[[@B89-cancers-12-00855]\]
  *Piper longum*                          Fruit                46 nm/spherical                                     24 h              67 μg/mL                       \[[@B99-cancers-12-00855]\]
  *Quercus (genus)*                       Fruit hull           40 nm/spherical                                     \-                50 μg/mL                       \[[@B92-cancers-12-00855]\]
  *Rheum emodi*                           Root                 27.5 nm/spherical                                   24 h              Dose dependent                 \[[@B102-cancers-12-00855]\]
  *Sesbania grandiflora*                  Leaf                 22 nm/spherical                                     24 h              20 μg/mL                       \[[@B93-cancers-12-00855]\]
  *Solanum trilobatum*                    Fruit                41.90 nm/spherical, polygonal                       \-                30 μg/mL                       \[[@B98-cancers-12-00855]\]
  *Syzygium cumini*                       Flower               \<40 nm/spherical                                   6 h               Dose dependent                 \[[@B95-cancers-12-00855]\]
  *Syzygium aromaticum*                   Fruit                5--20 nm/spherical                                  20 min            70 µg/mL                       \[[@B104-cancers-12-00855]\]
  *Tabernae montana divaricate*           Leaf                 Mean 22.85 nm/spherical                             24 h              20 μg/mL                       \[[@B90-cancers-12-00855]\]
  *Taxus baccata*                         Needles              Mean 75.1 nm/spherical                              48 h              0.25 mg/mL                     \[[@B40-cancers-12-00855]\]
  *Ulva lactuca*                          Whole                56 nm/spherical                                     10 min            37 µg/mL                       \[[@B105-cancers-12-00855]\]

cancers-12-00855-t003_Table 3

###### 

Studies of plant extracts for the biosynthesis of anticancer AgNPs (brain, cervical and colon cancers cell lines).

  Cancer                        Plant                  Part Used                         NP Size/NP Shape                 Incubation Time      Cell Line                      IC~50~                         Ref.
  ----------------------------- ---------------------- --------------------------------- -------------------------------- -------------------- ------------------------------ ------------------------------ ------------------------------
  **Brain Cancer**              *Butea monosperma*     Leaf                              20--80 nm/spherical              2 h                  HNGC2                          Dose dependent                 \[[@B101-cancers-12-00855]\]
  **Cervical Cancer**           *Azadirachta indica*   Leaf                              2--18 nm/triangular, hexagonal   \-                   Siha                           ≤4.25 μg/mL                    \[[@B106-cancers-12-00855]\]
  *Acorous calamus*             Rhizome                31.86 nm/spherical                20 h                             HeLa                 Dose dependent                 \[[@B107-cancers-12-00855]\]   
  *Azadirachta indica*          Leaf                   \<40 nm/spherical                 6 h                              Dose dependent       \[[@B95-cancers-12-00855]\]                                   
  *Calotropis gigantea*         Latex                  5--30 nm/spherical                24 h                             Dose dependent       \[[@B108-cancers-12-00855]\]                                  
  *Cymodocea serrulata*         Whole                  17--29 nm/spherical               2 h                              107.7 (GI~50~)       \[[@B109-cancers-12-00855]\]                                  
  *Heliotropium indicum*        Leaf                   80--120 nm/spherical              2 h                              20 μg/mL             \[[@B110-cancers-12-00855]\]                                  
  *Melia azedarach*             Leaf                   78 nm/cubical, spherical          10 min                           300 μg/mL (LD~50~)   \[[@B23-cancers-12-00855]\]                                   
  *Moringa olifera*             Stem bark              38--40 nm/spherical, pentagonal   24 h                             Dose dependent       \[[@B25-cancers-12-00855]\]                                   
  *Podophyllum hexandrum*       Leaf                   14 nm/spherical                   30--150 min                      20 μg/mL             \[[@B111-cancers-12-00855]\]                                  
  *Sargassum vulgare (algae)*   Whole                  10 nm/spherical                   3 h                              Dose dependent       \[[@B112-cancers-12-00855]\]                                  
  *Syzygium cumini*             Flower                 \<40 nm/spherical                 6 h                              Dose dependent       \[[@B95-cancers-12-00855]\]                                   
  **Colon Cancer**              *Plumeria alba*        Flower                            36.19 nm/spherical               30 min               COLO 205                       5.5 μg/mL                      \[[@B113-cancers-12-00855]\]
  *Rosa indica*                 Petal                  23.52--60.83 nm/spherical         1 h                              HCT 15               30 μg/mL                       \[[@B114-cancers-12-00855]\]   
  *Vitex nigundo*               Leaf                   22 nm/spherical                   4 h                              20 μg/mL             \[[@B115-cancers-12-00855]\]                                  
  *Citrullus colocynthis*       Leaf                   13.37 nm/spherical                24 h                             HCT-116              \>30 μg/mL                     \[[@B103-cancers-12-00855]\]   
  Roots                         7.39 nm/spherical      24 h                              \>30 μg/mL                                                                                                          
  Seeds                         16.57 nm/Spherical     24 h                              \>30 μg/mL                                                                                                          
  Fruit                         19.26 nm/spherical     24 h                              21.2 μg/mL                                                                                                          
  *Commelina nudiflora L.*      Whole                  24--80 nm/spherical, triangular   24 h                             100 μg/mL            \[[@B61-cancers-12-00855]\]                                   
  *Gymnema sylvestre*           Leaf                   -/spherical                       24 h                             HT29                 85 μg/mL                       \[[@B116-cancers-12-00855]\]   
  *Ulva lactuca (algae)*        Whole                  56 nm/spherical                   10 min                           49 μg/mL             \[[@B105-cancers-12-00855]\]                                  

NP---nanoparticle.

cancers-12-00855-t004_Table 4

###### 

Studies using plant extracts for the biosynthesis of AgNPs that inhibited epidermoid, laryngeal, gastronomic, hepatic, intestinal and kidney cancers cell lines.

  Cancer                        Plant                       Part Used                   NP Size/NP Shape            Incubation Time                Cell Line                      IC~50~                         Ref.
  ----------------------------- --------------------------- --------------------------- --------------------------- ------------------------------ ------------------------------ ------------------------------ ------------------------------
  Epidermoid Cancer             *Acorus calamus*            Rhizome                     59 nm/cuboidal, spherical   5--60 min                      A431                           78.58 μg/mL                    \[[@B117-cancers-12-00855]\]
  *Cucurbita maxima*            Petal                       76 nm/cuboidal, spherical   5--60 min                   82.39 μg/mL                                                                                  
  *Moringa oleifera*            Leaf                        94 nm/cuboidal, spherical   5--60 min                   83.57 μg/mL                                                                                  
  Gastric Cancer                *Artemisia marschalliana*   Aerial Part                 5--50 nm/spherical          5 min                          AGS                            21.05 μg/mL                    \[[@B118-cancers-12-00855]\]
  Hepatic Cancer                *Allium sativum*            Whole                       100--1200 nm/spherical      48 h                           HEP-G2                         31.25 ng/mL (LD~50~)           \[[@B119-cancers-12-00855]\]
  *Citrullus colocynthis*       Leaf                        13.37 nm/spherical          24 h                        Hep-G2                         10.02 μg/mL                    \[[@B97-cancers-12-00855]\]    
  Root                          7.39 nm/spherical           24 h                        17.2 μg/mL                                                                                                               
  Seed                          16.57 nm/spherical          24 h                        \>30 μg/mL                                                                                                               
  Fruit                         19.26 nm/spherical          24 h                        22.4 μg/mL                                                                                                               
  *Erythrina indica*            Root                        20--118 nm/spherical        Overnight                   13.86 (% viability at 25 μL)   \[[@B75-cancers-12-00855]\]                                   
  *Panax ginseng*               Leaf                        \-                          \-                          Dose dependent                 \[[@B89-cancers-12-00855]\]                                   
  *Rubus glaucus Benth*         Leaf                        12--50 nm/Quasi-spherical   48 h                        Dose dependent                 \[[@B120-cancers-12-00855]\]                                  
  Intestinal Cancaer            *Taxus yunnanensis*         Callus                      6.4--27.2 nm/spherical      10 min                         SMMC-7721                      27.75 μg/mL                    \[[@B124-cancers-12-00855]\]
  Intestinal Cancaer            *Citrullus colocynthis*     Leaf                        13.37 nm/spherical          24 h                           Caco-2                         \>30 μg/mL                     \[[@B97-cancers-12-00855]\]
  Root                          7.39 nm/spherical                                                                                                                                                                
  Seed                          16.57 nm/spherical                                                                                                                                                               
  Fruit                         19.26 nm/spherical                                                                                                                                                               
  Kidney Cancer                 *Azadirachta indica*        Leaf                        \<40 nm/spherical           6 h                            Hek-293                        Dose dependent                 \[[@B95-cancers-12-00855]\]
  *Syzygium cumini*             Flower                      \<40 nm/spherical           6 h                         Dose dependent                 \[[@B98-cancers-12-00855]\]                                   
  Laryngeal Cancer              *Citrullus colocynthis*     Callus                      31 nm/spherical             24 h                           Hep-2                          3.42 μg/mL                     \[[@B121-cancers-12-00855]\]
  *Suaeda monoica*              Leaf                        31 nm/spherical             5 h                         500 nM, AgNPs conc.            \[[@B122-cancers-12-00855]\]                                  
  *Ulva lactuca (algae)*        Whole                       56 nm/spherical             10 min                      12.5 μg/mL                     \[[@B105-cancers-12-00855]\]                                  
  Leukemia Cancer               *Dimocarpus longan*         Peel                        8--22 nm/spherical          2 h                            H1299                          5.33 μg/mL                     \[[@B123-cancers-12-00855]\]
  *Sargassum vulgare (algae)*   Whole                       10 nm/spherical             3 h                         HL-60                          Dose dependent                 \[[@B112-cancers-12-00855]\]   

NP: nanoparticle.

cancers-12-00855-t005_Table 5

###### 

List of studies using plant extracts for the biosynthesis of AgNPs that inhibited cell lines of lung cancer, lymphoma, melanoma, oral cancer, ovarian cancer, pancreatic cancer and prostate cancers.

  Cancer                                Plant                       Part Used                  NP Size/NP Shape          Incubation Time                  Cell Line                      IC~50~                         Ref.
  ------------------------------------- --------------------------- -------------------------- ------------------------- -------------------------------- ------------------------------ ------------------------------ ------------------------------
  Lung Cancer                           *Acorous calamus*           Rhizome                    31.86 nm/spherical        20 h                             A549                           Dose dependent                 \[[@B106-cancers-12-00855]\]
  *Artemisia princeps*                  Leaf                        20 nm/spherical            15 min                    Time dependent                   \[[@B125-cancers-12-00855]\]                                  
  *Butea Monosperma*                    Leaf                        20--80 nm/spherical        2 h                       Dose dependent                   \[[@B101-cancers-12-00855]\]                                  
  *Croton bonplandianum*                Leaf                        32 nm/spherical            1 h                       Dose dependent                   \[[@B128-cancers-12-00855]\]                                  
  *Cymodocea serrulata*                 Leaf                        29.28 nm/spherical         1 h                       100 μg/mL (LD~50~)               \[[@B130-cancers-12-00855]\]                                  
  *Gossypium hirsutum*                  Leaf                        13--40 nm/spherical        3 min                     40 μg/mL                         \[[@B126-cancers-12-00855]\]                                  
  *Olax scandens*                       Leaf                        30--60 nm/spherical        2 h                       Dose dependent                   \[[@B75-cancers-12-00855]\]                                   
  *Origanum vulgare*                    Leaf                        136 ± 10.09 nm/spherical   Temp. dependent           100 μg/mL (LD~50~)               \[[@B42-cancers-12-00855]\]                                   
  *Panax ginseng*                       Leaf                        \-                         \-                        Dose dependent                   \[[@B89-cancers-12-00855]\]                                   
  *Penicillium decumbens (MTCC 2494)*   Whole                       30--60 nm/spherical        \-                        80 μg/mL, 24 h, 60 μg/mL, 48 h   \[[@B129-cancers-12-00855]\]                                  
  *Rosa damascena*                      Petal                       15--27 nm/spherical        0--25 min                 80 μg/mL                         \[[@B131-cancers-12-00855]\]                                  
  *Scoparia dulcis*                     Leaf                        15--25 nm/spherical        1 h                       Dose dependent                   \[[@B127-cancers-12-00855]\]                                  
  *Syzygium aromaticum*                 Fruit                       5--20 nm/spherical         20 min                    70 µg/mL                         \[[@B104-cancers-12-00855]\]                                  
  Lymphoma Cancer                       *Abelmoschus esculentus*    Pulp                       \~6.7 nm/spherical        27 h                             Jurkat                         16.15 μg/mL                    \[[@B132-cancers-12-00855]\]
  Melanoma Cancer                       *Excoecaria agallocha L.*   Leaf                       228 nm/-                  \-                               B16F10                         7.6 ± 0.8 μg/mL                \[[@B133-cancers-12-00855]\]
  *Butea monosperma*                    Leaf                        20--80 nm/spherical        2 h                       Dose dependent                   \[[@B101-cancers-12-00855]\]                                  
  Oral Cancer                           *Haliclona exigua*          Whole                      100--120 nm/flower-like   10 min                           KB                             0.6 μg/mL                      \[[@B134-cancers-12-00855]\]
  Ovarian Cancer                        *Croton bonplandianum*      Leaf                       32 nm/spherical           1 h                              PA1                            7.5 μg/mL                      \[[@B125-cancers-12-00855]\]
  *Scoparia dulcis*                     Leaf                        150--25 nm/spherical       1 h                       Dose dependent                   \[[@B127-cancers-12-00855]\]                                  
  Pancreatic Cancer                     *Dimocarpus longan*         Peel                       8--22 nm/spherical        2 h                              BxPC 3                         38.9 μg/mL                     \[[@B123-cancers-12-00855]\]
  Prostate Cancer                       *Alternanthera sessilis*    Leaf                       300--50 nm/spherical      6 h                              PC3                            6.85 μg/mL                     \[[@B76-cancers-12-00855]\]
  *Dimocarpus longan Lour.*             Peel                        9--32 nm/cubic             5 h 20 min                Dose dependent                   \[[@B136-cancers-12-00855]\]                                  
  *Gracilaria edulis*                   Whole                       55--99 nm/spherical        \-                        53.99 μg/mL                      \[[@B135-cancers-12-00855]\]                                  
  *Dimocarpus longan*                   Peel                        8--22 nm/spherical         Overnight                 VCaP                             87.33 μg/mL                    \[[@B123-cancers-12-00855]\]   

NP---nanoparticle.

[^1]: These authors contributed equally to this work.
